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Abstract In the current work we present some pharma-
cological characteristics of ten new analogues of bradykinin
(Arg–Pro–Pro–Gly–Phe–Ser–Pro–Phe–Arg) modiﬁed in the
N-terminal part of the molecule with a variety of acyl sub-
stituents. Of the many acylating agents used previously with
B2 receptor antagonists, the following residues were chosen:
1-adamantaneacetic acid (Aaa), 1-adamantanecarboxylic
acid (Aca), 4-tert-butylbenzoic acid (t-Bba), 4-aminobenzoic
acid (Aba), 12-aminododecanoic acid (Adc), succinic acid
(Sua), 4-hydroxybenzoic acid, 4-hydroxy-3-methoxybenzoic
acid, 3-(4-hydroxyphenyl)propionic acid and 6-hydroxy-2-
naphthoic acid. Biological activity of the compounds was
assessed in the in vivo rat blood pressure test and the in vitro
rat uterus test. Surprisingly, N-terminal substitution of the
bradykinin peptide chain itself with aforementioned groups
resulted in antagonists of bradykinin in the pressor test and
suppressed agonistic potency in the uterotonic test. These
interesting ﬁndings need further studies as they can be
helpful for designing more potent B2 receptor blockers.
Keywords Bradykinin analogues  B2 receptor
antagonists  Bulky acyl groups  In vivo rat blood pressure
test  In vitro rat uterus test
Abbreviations
Aaa 1-Adamantaneacetic acid
Aba 4-Aminobenzoic acid
Aca 1-Adamantanecarboxylic acid
Adc 12-Aminododecanoic acid
Asa N-(1-adamantyl)succinamide
Ata 9-Anthracenecarboxylic acid
Pal Palmitic acid
Sua Succinic acid
t-Bba 4-Tert-butylbenzoic acid
X1 4-Hydroxybenzoic acid
X2 4-Hydroxy-3-methoxybenzoic acid
X3 3-(4-Hydroxyphenyl)propionic acid
X4 6-Hydroxy-2-naphthoic acid
Introduction
The kallikrein-kinin system represents a metabolic cascade
that, when activated, triggers the release of vasoactive kinins
(Moreau et al. 2005). This complex multi-protein system
includes the serine proteases tissue and plasma kallikreins,
which liberate kinins from high- and low-molecular-weight
kininogen (HK and LK, respectively). Kinins exert their
pharmacological activities by binding speciﬁc receptors,
before being metabolized by various peptidases. In humans
and in most mammals, the term ‘‘kinin’’ refers to the non-
apeptide bradykinin (BK, Arg–Pro–Pro–Gly–Phe–Ser–Pro–
Phe–Arg), the decapeptide kallidin (KD: Lys-BK), and their
carboxy-terminal des-Arg metabolites. By virtue of their
ability to activate endothelial cells, it comes to vasodilation,
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DOI 10.1007/s10989-011-9285-5increased vascular permeability, release of tissue-type plas-
minogen activator (t-PA), production of nitric oxide (NO),
and mobilization of arachidonic acid, among others. They
participate in physiological processes (regulation of blood
pressure, renal and cardiac functions) as well as in patho-
logical ones (like inﬂammation).
There are two pharmacologically distinct kinin receptor
subtypes, known as B1 and B2.B 2 receptors are ubiquitous
and constitutively expressed in a wide variety of cells, and
require the full peptide chain of BK as an agonist. They
respond similarly to KD and Met-Lys-BK. In contrast, B1
receptors have normally a very limited expression, but the
receptor gene is turned on in chronic inﬂammation. They
are activated by carboxypeptidase degradation products of
BK and KD which are [des-Arg
9]-BK and [des-Arg
10]-KD,
respectively (Marceau 1995; Marceau et al. 1998). These
kinin receptors belong to the large family of rhodopsin G
protein-coupled receptors (GPCR) and are responsible for
the transduction of extracellular signals to intracellular G
proteins, which act as effectors to generate second mes-
sengers (Lefkowitz 2000).
The role played by the kallikrein-kinin system in
inﬂammation has been extensively studied and reviewed
(UenoandOh-Ishi2003).Asagreatnumberofdiseasestates
such as chronic inﬂammatory pain, edema, asthma, and
sepsis have their basis in the inﬂammatory response, the
development of antagonist drugs targeted at the B1 and B2
receptorsprovidesanoveltherapeuticopportunityapproach.
Potentialmedicinalapplicationsofthekininreceptorligands
(notnecessarilyantagonists)includealsocardiovascularand
renal disorders, pain, diabetes, and probably cancer.
The aforementioned listing of different types of BK
functions illustrates why the search for antagonists of this
hormone started immediately after announcement of its
structure in 1960 (Boissonnas et al. 1960). In many labo-
ratories, investigation of structural features which might
produce potent and selective B2 receptors blockers resulted
in the synthesis and pharmacological evaluation of thou-
sands of compounds exhibiting various activity proﬁles.
However, the breakthrough in this ﬁeld took place in the
early 1990s, when potent BK antagonists, carrying con-
formationally constrained amino acid residues in their
C-terminal parts were synthesized (Hock et al. 1991), thus
substantially improving the quality of the ﬁrst antagonist
(Vavrek and Stewart 1985).
Until the 90’s of the last century, acylation of the
N-terminus of BK antagonists was considered to suppress
their side agonistic activity. At the same time researchers
believed that this modiﬁcation did not enhance the antag-
onistic potency of the compounds and in some cases even
caused its reduction (Steranka et al. 1988; Steranka et al.
1989; Schachter et al. 1987; Regoli et al. 1991; Rhaleb
et al. 1991). The change in this thinking came with the
design of two analogues in our laboratory based on the
structure of the potent antagonist [D-Arg
0, Hyp
3,T h i
5,8,
D-Phe
7]-BK previously described by the Stewart’s group
(Schachter et al. 1987). It turned out that N-terminal sub-
stitution using bulky groups such as 1-adamantaneacetic
acid (Aaa) or 1-adamantanecarboxylic acid (Aca)—resul-
ted in a signiﬁcant increase in B2 antagonistic activity in
the rat blood pressure test (Lammek et al. 1990, 1991). Our
subsequent ﬁndings have shown that acylation of the
Stewart’s peptide with 4-tert-butylbenzoic acid (t-Bba),
palmitic acid (Pal) or N-(1-adamantyl)succinamide (Asa)
intensiﬁed the antagonistic properties. An analogue con-
taining 9-anthracenecarboxylic acid (Ata) residue in its
N-terminus displayed a weak antagonistic potency. With
compounds acylated with either the positively or nega-
tively charged acyl substituent (9-acridinecarboxylic acid
(Ana) and phthalic acid (Fta), respectively) we have
noticed inversion of the activity (from antagonistic to
agonistic one) in the rat uterus test (Trzeciak et al. 2000).
The results obtained for analogues substituted with the
12-aminododecanoic acid (Adc), 4-aminobenzoic acid
(Aba) or succinic acid (Sua) residues did not conﬁrm our
previous observations suggesting that charged acyl groups
have a negative impact on B2 antagonism (Dawidowska
et al. 2005). Subsequently we synthesized a series of
compounds by acylation of the Stewart’s antagonist with
substituted benzoic acids (4-hydroxy-3-metoxybenzoic
acid, 4-hydroxybenzoic acid and 3-hydroxy-4-methylben-
zoic acid) and propionic acids (3-(2-hydroxyphenyl)pro-
pionic and 3-(4-hydroxyphenyl)propionic acids) as well as
with 1-hydroxy-2-naphthoic acid and 2-nornbornaneacetic
acid (Labudda et al. 2007). Biological evaluation revealed
that modiﬁcations used in that study led either to
enhancement or retention of antagonistic potency of the
model peptide with only a few exceptions (4-hydroxy-
benzoic acid, 1-hydroxy-2-naphthoic acid and 2-norn-
bornaneacetic acid residues).
The conclusions drawn from abovementioned research
indicate positive inﬂuence of acylation of the N-terminus of
the Stewart’s antagonist with bulky substituents on phar-
macological properties of the resulting peptides. However,
when designing such compounds one should take into con-
sideration the size and chemical character as well as the
distance of the acyl group from the main peptide skeleton.
On the contrary, we also reported that in case of some BK
antagonists, which are sterically restricted in their C-terminal
part, acylation cannot improve the antagonistic activity or
even leads to its reduction (forexample analogues containing
1-naphthyl-L-alanine (L-1-Nal), 2-naphthyl-L-alanine (L-2-
Nal), 2-naphthyl-D-alanine (D-2-Nal) or 1-aminocyclohex-
ane-1-carboxylicacid(Acc)residuesandanethylene-bridged
dipeptide fragment: -&Phe-(&)Phe- or -&D-Phe-(&)D-Phe-)
(Prahl et al. 1997; Trzeciak et al. 2000; Prahl et al. 2002,
118 Int J Pept Res Ther (2012) 18:117–124
1232003; Labudda-Dawidowska et al. 2005). The data acquired
so far in our laboratory are not sufﬁcient to formulate any
straightforward rule concerning the relationship between
antagonistic properties of BK analogues and the type of
N-terminal modiﬁcation. Thus this issue certainly requires
further studies.
Since the discovery of the ﬁrst antagonists for the B2
receptor in 1984 (Vavrek and Stewart 1985), efforts of
researchers to ﬁnd more potent selective and enzyme-
degradation resistant blockers concentrated on the synthe-
sis of analogues with single or multiple substitutions in the
chain of the BK molecule. Our recent idea of acylation of
the N-terminus of the natural signal peptide BK with var-
ious bulky groups is a quite new approach to this search.
BK acylated with the Ana or Ata residues exhibited weak
antagonistic activity in the rat blood pressure test and its
agonistic potency in the rat uterus assay was decreased to 5
and 14%, respectively (Prahl 2007). In the present work we
decided to use ten acyl substituents, which were previously
applied to modiﬁcation of the Stewart’s antagonist. The
structures of the new compounds are shown below and the
structures of the acyl substituents are presented in Fig. 1.
Z–Arg–Pro–Pro–Gly–Phe–Ser–Pro–Phe–Arg
Z = 1-adamantaneacetic acid (Aaa) (analogue I)
Z = 1-adamantanecarboxylic acid (Aca) (analogue II)
Z = 4-tert-butylbenzoic acid (t-Bba) (analogue III)
Z = 4-aminobenzoic acid (Aba) (analogue IV)
Z = 12-aminododecanoic acid (Adc) (analogue V)
Z = succinic acid (Sua) (analogue VI)
Z = 4-hydroxybenzoic acid (X1) (analogue VII)
Z = 4-hydroxy-3-methoxybenzoic acid (X2) (analogue
VIII)
Z = 3-(4-hydroxyphenyl)propionic acid (X3) (analogue
IX)
Z = 6-hydroxy-2-naphthoic acid (X4) (analogue X)
Materials and Methods
General
TLC was carried out on silica plates (Merck) and the spots
were visualized with iodine. The solvent system used was
butan-1-ol/acetic acid/water/ethyl acetate (1:1:1:1, v/v).
HPLC was carried out on a Waters (analytical and pre-
parative) chromatograph equipped with a UV detector
(k = 226 nm). The following solvent system was used:
[A] 0.1% aqueous TFA and [B] acetonitrile in 0.1% aqueous
TFA (80:20, v/v). Semi-preparative HPLC was carried out
using a Waters C18 column (15 lm, 100 A ˚;7 . 89 300 mm)
in a linear gradient from 20 to 40% of [B] for 60 min
(analogues I–III), and from 15 to 30% of [B] for 60 min
(analogues IV–X), all at a ﬂow rate of 2.5 ml/min. The mass
spectra of the peptides were recorded on a MALDI TOF
mass spectrometer (Biﬂex III Bruker, k = 337 nm). The
purity of the peptides was determined on a Hypersil C18
column (5 lm, 100 A ˚,4 . 69 250 mm). Linear gradients
Fig. 1 Structures of N-terminal
substituents used in the study:
a 1-adamantaneacetic acid (Aaa),
b 1-adamantanecarboxylic acid
(Aca), c 4-tert-butylbenzoic acid
(t-Bba), d 4-aminobenzoic acid
(Aba), e 12-aminododecanoic
acid (Adc), f succinic acid (Sua),
g 4-hydroxybenzoic acid (X1),
h 4-hydroxy-3-methoxybenzoic
acid (X2), i 3-(4-hydroxyphenyl)
propionic acid (X3)a n d
j 6-hydroxy-2-naphthoic
acid (X4)
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20 to 80% of [B] for 30 min (analogues IV–X)w e r ea p p l i e d
at a ﬂow rate of 1 ml/min.
All the amino acid derivatives were purchased from
NovaBiochem, except for 1-adamantaneacetic acid,
1-adamantanecarboxylic acid, 4-tert-butylbenzoic acid,
Fmoc-4-aminobenzoic acid, Fmoc-12-aminododecanoic
acid, succinic acid, 4-hydroxybenzoic acid, 4-hydroxy-3-
methoxybenzoic acid, 3-(4-hydroxyphenyl)propionic acid
and 6-hydroxy-2-naphthoic acid, which were provided by
Sigma-Aldrich, Co.
Peptide Synthesis
All the peptides (BK, Stewart’s antagonist (SA) and ana-
logues I–X) were obtained by the solid-phase method on a
Symphony Multiple Peptide Synthesizer (Protein Tech-
nologies Inc., USA) using the Fmoc-strategy and starting
from Fmoc-Arg(Pbf)-Wang resin (capacity 0.4 mmol/g,
25 lmol scale). The amino acid side chain protecting
groups were Bu
t for Ser and Hyp and 2,2,4,6,7-penta-
methyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg. Fully
protected peptide resins were synthesized according to
standard procedures (Bodanszky and Bodanszky 1984)
involving (i) deprotection steps using a 20% solution of
piperidine in DMF, 5 and 10 min and (ii) couplings in
DMF using TBTU, HOBt in the presence of NMM. The
amino acids were coupled at a ﬁvefold excess. N-terminal
acyl groups were attached in the ﬁnal coupling step using
the same procedure as that for Fmoc-amino acids. After
completion of the synthesis, the protected peptidyl resins
were treated with TFA (triﬂuoroacetic acid):H2O:triiso-
propylsilane (TIS) (95.5:2.5:2.5, v/v/v) and stirred for 4 h.
Solutions of the cleaved peptides were ﬁltered and evap-
orated in vacuo to a volume of about 1 ml. Then the
peptides were precipitated with diethyl ether to afford
crude products. The solvents were evaporated under
reduced pressure and the resulting materials were dissolved
in water, frozen, and lyophilized. The crude peptides were
desalted on a Sephadex G-15 column, and eluted with
aqueous acetic acid (30%) at a ﬂow rate of 3 ml/h. Frac-
tions comprising the major peak were freeze-dried and
puriﬁed by RP-HPLC as described above. The purity of the
peptides was checked using analytical HPLC. MALDI
TOF mass spectrometry (molecular ion) was used to con-
ﬁrm the identity of the pure compounds.
Biological Evaluation
The in vivo rat blood pressure test: The ability of the BK
analogues to inhibit the vasodepressor response to exoge-
nous BK in conscious rats was assessed. Male Wistar rats
were maintained on a regular chow diet and tap water at
ambient temperature (22 ± 1C). The assay was based on
the previously published procedure (Labudda-Dawidowska
et al. 2005; Labudda et al. 2006, 2007) with minor modi-
ﬁcations. Handling of the experimental animals was done
under supervision of the local Ethics Committee of the
Medical University of Gdan ´sk.
The rats had two arteries catheterized. A Micro-Rena-
thane
 polyurethane based elastomer tubing (MRE-040,
Braintree Scientiﬁc, USA) was inserted into the left carotid
artery, while a RenaPulse
 High Fidelity Pressure Tubing
(RPT 040, Braintree Scientiﬁc, USA) with a tip made of
Micro-Renathane
 MRE-040 tubing was indwelled into
the right iliac artery. Both catheters were exteriorized
subcutaneously at the back of the neck. A Y-type connector
was mounted to the carotid artery line. Following a
40–44 h recovery, mean arterial pressure (MAP) and heart
rate (HR) were monitored through a Gould-Statham P23-
ID pressure transducer (Gould, Cleveland, OH, USA)
connected to the iliac catheter. Angiotensin converting
enzyme (kininase II) inhibitor, enalapril (Merck Sharp and
Dohme Research Lab., Rahway, NJ, USA; 1 mg/kg), was
injected into the iliac artery to stabilize the blood pressure.
To provide homogeneity of further assay, rats with MAP
within the range of 85–125 mmHg and HR 270–360 beats/
min were arbitrarily enrolled to the study. Two doses of BK
(BK acetate salt; Sigma, USA), 125 or 250 ng per animal,
100 and 200 ll, respectively, of 1.25 lg/ml solution in 5%
D-glucose, were randomly injected four to ﬁve times, every
4–5 min, into one branch of the carotid catheter. The rats
which exhibited vasodepressor response to 250 ng BK
(DMAP) within the range of 20–45 mmHg were enrolled to
the study. In accordance with the previous study (Labudda
et al. 2007), those rats which displayed the vasodepressor
response to 125 ng BK higher than 82% of that evoked by
250 ng BK were excluded from testing. The BK dose of
250 ng was used as a standard in further assay.
The BK analogues dissolved in the 5% D-glucose were
infused (constant infusion rate 80 ll/min) to the other
branch of the carotid catheter. The testing was initiated with
the 10-min infusion at a concentration of 1 lg/ml (this gave
ad o s eo f0 . 0 8lg/min/rat). During this infusion, the 250 ng
dose of BK was injected twice: at 270 s and at 570 s. The
concentration of the infused BK antagonist was then
increased to 4, 16, 64, 256, 1024 lg/ml and, if necessary, up
to 2048 or 3580 lg/ml, to give the doses of 0.32, 1.28, 5.12,
20.48, 81.92, 163.84 and 286.40 lg/min/rat, respectively.
T h ei n f u s i o no fB Ka n a l o g u ea tc o n c e n t r a t i o n so f1 0 2 4lg/
ml and higher was limited to 5 min and BK was injected
only once by the end of the infusions. As soon as the
vasodepressor response to BK was lower than 10% of the
standard response, the procedure was completed.
The percent inhibition of the vasodepressor response to
250 ng BK by the tested BK antagonist was plotted against
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123the logarithm of the dose. From these dose response curves,
effective doses ED20,E D 50 and ED90, were determined
representing doses of the BK antagonist (lg/min) that
inhibited vasodepressor response to the agonist (250 ng of
BK) by 20, 50 and 90%, respectively. The results are
reported as mean values ± SEM.
The in vitro rat uterus test: All the analogues were
evaluated in the uterotonic assay using a modiﬁed Holton’s
method (Holton 1948) in the Munsick solution (Munsick
1960)onastripofratuterus. Wistarratsinestrusinducedby
injectionofestrogen48 hbeforetheexperimentswere used.
Handling of the experimental animals was done under
supervision of the Ethics Committee of the Academy of
Sciences according to §23 of the law of the Czech Republic
no. 246/1992. BK was used as a standard over a concen-
tration range of 10 pM to 10 nM. Cumulative dose–
response curves were constructed both in the absence and
presence of various concentrations of the analogues, i.e.
doses of BK were added successively to the organ bath in
doubled concentrations and at 1-min intervals, without the
ﬂuid being changed, until the maximum contraction of the
uterine tissue was obtained. The height of a single isometric
contraction in response to different doses of BK was mea-
sured. The antagonist was applied to the organ bath 1 min
prior to the cumulative dosing of BK. The antagonistic
activity was expressed as pA2, i.e. the negative common
logarithm of the analogue concentration which shifted the
dose–response curve of BK by a factor of two (comparison
of the linear portions of the dose–response curves). Each
analogue was tested on uteri taken from 3 to 5 rats. As far as
the agonistic activity of the analogues is concerned, it was
calculated by comparing the threshold doses of cumulative
dose–response curves of the analogue and that of standard
BK. The activity of BK was taken as 100%.
Results
The ten new analogues of BK (I–X) were obtained as crude
products in satisfactory yields. After HPLC puriﬁcation,
their purity was higher than 98% as determined by ana-
lytical HPLC. The MALDI TOF mass spectrometry con-
ﬁrmed that the puriﬁed peptides were the desired products.
Physicochemical properties of the new compounds are
presented in Table 1.
PharmacologicalcharacteristicsofanaloguesI–Xtogether
with thoseof Stewart’s antagonist(used asa positive control)
and some related peptides are summarized in Table 2.T h e
potency was assayed in the in vivo rat blood pressure test
using conscious rats and in the in vitro rat uterus test as
described in the ‘‘Materials and Methods’’ section.
In the rat blood pressure test compounds I–X displayed
antagonistic activity, the potency of this effect varying
from very low (peptides IV and VIII), through moderate
(peptides II, III, V, VI, VII and IX) to equivalent to that of
the acylated Stewart’s antagonist (peptide I).
Four out of the ten tested analo elicited also direct
vasodepressor response at doses below 1 lg/min (II, IV
and IX)o r5lg/min (VIII), most of the analogues showing
very weak antagonism. Although endogenous BK is not the
major vasodilatory contributor that takes part in the regu-
lation of arterial pressure, the evoked decrease in MAP is
likely to suggest some BK agonistic potency. On the other
hand, all of the aforementioned peptides substantially
inhibited the vasodepressor responses to exogenous BK
that is a proof and quantitative measure of their antago-
nistic potency. The source of these discrepancies remains
vague. The point is that direct agonist-like effect of the BK
analogues on blood pressure not necessarily reﬂects their
interaction with BK receptors responsible for vasodilation
caused by injection of exogenous BK. The standard
decrease in MAP noticed following BK injection is
strongly related to vasodilation of small arteries of the
resistance type. This is not the case in the direct vasode-
pressor response observed during infusion of some BK
analogues. Such response is likely to involve either relax-
ation of smooth muscle in larger arteries or to result from
deregulation of central blood pressure (Bomtempo et al.
1998; Madeddu et al. 1999; Milan et al. 2005). It is well
known that BK receptors, including those of B2 type, are
not homogenous in the vasculature and in the regulatory
circuits of the central nervous system (Odya et al. 1980;
Plevin and Owen 1988; Bomtempo et al. 1998; Bascands
et al. 2003). Probably, some BK analogues bind to one,
rather narrow pool of BK receptors, to activate the cellular
response and simultaneously block the other pool of BK
Table 1 Physicochemical properties of analogues I–X
Analogue Formula HPLC TR
(min)
MW [M ? H]
?
Calculated Found
I C62H90N15O12 43.1
a 1235.2 1236.0
II C61H88N15O12 41.9
a 1222.4 1222.7
III C61H86N15O12 44.0
a 1220.4 1220.9
IV C57H79N15O12 19.9
b 1179.3 1179.4
V C62H96N16O12 17.3
b 1257.5 1257.9
VI C54H78N15O14 18.6
b 1160.3 1160.4
VII C57H78N15O14 19.8
b 1180.3 1180.2
VIII C58H80N15O14 22.4
b 1210.4 1210.2
IX C59H82N15O13 20.4
b 1208.4 1208.3
X C61H79N15O13 17.6
b 1230.4 1230.7
a Linear gradient from 1 to 80% of [B] for 60 min
b Linear gradient from 20 to 80% of [B] for 30 min
The following solvent system was used: [A] 0.1% aqueous TFA and
[B] acetonitrile in 0.1% aqueous TFA (80:20, v/v)
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stream (Madeddu et al. 1999; Bascands et al. 2003; Milan
et al. 2005).
In the rat uterus test all the analogues turned out to be
agonists. In case of peptide I, V, IX and X, the agonistic
activity was reduced to 25, 43, 24 and 13% of the BK
activity, respectively. Compounds II, VII and VIII
exhibited very weak agonistic properties, while analogues
III, IV and VI were practically inactive.
Discussion
The present study is a continuation of our previous inves-
tigations concerning the inﬂuence of the N-terminal struc-
ture of BK molecule on pharmacological properties of the
resulting compounds. Acylation of the N-terminus of the
antagonists, especially of the Stewart’s antagonist, was
studied thoroughly in the past (Lammek et al. 1990, 1991;
Prahl et al. 1997, 2002, 2003; Trzeciak et al. 2000;
Table 2 Pharmacological properties of the new BK analogues and corresponding data of related compounds
Analogue Vasodepressor potency
k Uterotonic potency: % of activity
of BK or pA2
m
ED20 (lg/min) ED50 (lg/min) ED90 (lg/min)
BK
a – – – 100 (%)
SA
b 0.43 ± 0.03 3.19 ± 0.33 52.60 ± 10.59 7.70 ± 0.13 (pA2)
I 0.57 ± 0.28 8.49 ± 3.03 13.57 ± 4.88 25 (%)
Aaa-SA
c 0.84 ± 0.09 – 13.94 ± 1.69 –
II 4.37 ± 1.99 336.95 ± 132.14
l 855.93 ± 339.66
l 2.4 (%)
Aca-SA
d 0.09 ± 0.02 – 4.23 ± 0.46 –
III 1.67 ± 0.39 94.21 ± 33.48 238.44 ± 85.12 0.4 (%)
t-Bba-SA
e 0.31 ± 0.10 – 12.70 ± 1.21 7.27 ± 0.03 (pA2)
IV 11.30 ± 3.13 1041.71 ± 310.00
l 2648.05 ± 794.33
l 1 (%)
Aba-SA
f 1.10 ± 0.14 5.99 ± 0.47 64.52 ± 13.28 7.04 ± 0.21 (pA2)
V 1.55 ± 0.35 23.71 ± 10.63 56.26 ± 23.85 43 (%)
Adc-SA
f 1.94 ± 0.25 7.65 ± 0.94 50.69 ± 9.46 7.55 ± 0.15 (pA2)
VI 6.02 ± 1.50 364.06 ± 87.29
l 722.20 ± 374.92
l 0.5 (%)
Sua-SA
f 1.17 ± 0.20 8.30 ± 0.56 112.89 ± 11.16 \6.0 (pA2)
VII 2.52 ± 1.18 80.47 ± 21.01 201.98 ± 52.47 2.8 (%)
X1-SA
g,h 0.46 ± 0.08 2.89 ± 0.31 36.36 ± 6.33 6.51 ± 0.19 (pA2)
VIII 24.63 ± 8.74 1896.96 ± 883.13
l 4815.70 ± 2258.54
l 3.8 (%)
X2-SA
i,h 0.18 ± 0.02 1.35 ± 0.13 20.17 ± 2.39 5.82 ± 0.30 (pA2)
IX 1.79 ± 0.52 48.85 ± 15.75 122.21 ± 40.25 24.5 (%)
X3-SA
j,h 0.29 ± 0.04 1.38 ± 0.11 13.47 ± 2.87 6.26 ± 0.10 (pA2)
X 6.22 ± 2.28 368.69 ± 160.27
l 933.81 ± 409.19
l 13.2 (%)
a Schachter et al. (1987)
b SA means Stewart’s antagonist. This peptide ([D-Arg
0, Hyp
3, Thi
5,8, D-Phe
7]-BK) was previously designed by Stewart’s group. As we used a
different assay for evaluation of biological activities, we tested this analogue in our reference system
c Lammek et al. (1990)
d Lammek et al. (1991)
e Trzeciak et al. (2000)
f Dawidowska et al. (2005)
g X1, 4-hydroxybenzoic acid
h Labudda et al. (2007)
i X2, 4-hydroxy-3-methoxybenzoic acid
j X3, 3-(4-hydroxyphenyl)propionic acid
k ED20,E D 50 and ED90 represent doses of BK antagonist (lg/min) that inhibit the vasodepressor response to 250 ng of BK by 20, 50 and 90%,
respectively
l Values ED50 or ED90 extrapolated from the dose–response curve
m Agonistic activity was calculated as percentage of the BK activity (set to 100%); antagonistic activity was calculated as pA2 (negative
common logarithm of analogue concentration shifting the log dose–response curve for BK by a factor of 0.3 to the right: the calculations were
made from the linear portions of the curves)
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123Dawidowska et al. 2005; Labudda-Dawidowska et al. 2005;
Labudda et al. 2007; Prahl 2007), while N-terminal substi-
tution of the parent BK peptide chain with 10 different acyl
groups is described here. The potency of the obtained ana-
logues with the acyl substituents follows the sequence:
Aaa[Adc[X3[X1 * tBba[Sua * Aca[X4[Aba[
X2. Surprisingly, simple acylation with Aaa resulted in
peptide (I)displaying highantagonisticpotencycomparable
to that of the Aaa-acylated Stewart’s antagonist (see
Table 2). On the other hand, BK acylated with Aca residue
(analogue II) exhibited very low antagonistic activity.
Compound III containing t-Bba residue, the residue which
increased antagonism of Stewart’s peptide (Trzeciak et al.
2000), turned out to be very weak B2 receptor blocker. Out
of the three acylated compounds(IV,V and VI), differing in
their chemical character (basic Aba and Adc residues and
the acidic Sua), only analogue V (Adc residue) showed high
antagonism similar to that of the Adc-acylated Stewart’s
peptide. It is worth emphasizing that acylation of the
Stewart’s antagonist with each of those three residues
caused either retention or enhancement of their antagonistic
properties (Dawidowska et al. 2005). Among other sub-
stituents containing in their structure benzene ring, namely
4-hydroxybenzoic acid (X1, analogue VII), 4-hydroxy-3-
methoxybenzoic acid (X2, analogue VIII), and 3-(4-
hydroxyphenyl)propionic acid (X3, peptide IX), only the
last-named one (IX) showed moderately high antagonism.
In this compound, the distance between the phenyl group
and the main peptide chain is larger than that in analogue
VII or VIII and the group is conformationally more ﬂexible
(similarly less conformationally restricted is Aaa in com-
parison to Aca). Finally the last peptide (X) modiﬁed with
the residue consisting of a planar naphthalene ring substi-
tuted at position 6 with a hydroxyl group (6-hydroxy-2-
naphthoic acid) was a very weak antagonist. Interestingly,
the compounds with the highest antagonistic potency in the
rat blood pressure test (I, V and IX) exhibited the highest
agonistic activity in the uterotonic test.
To sum up the results obtained for analogues I–X in the
rat blood pressure test, it can be stated that N-terminal
substitution of the BK molecule with selected acyl groups
led to antagonists, but the acyl substituents that caused
highest antagonism differ from ones which strongly
enhanced antagonism with the Stewart’s peptide. The rel-
atively simple idea of acylation of the unchanged BK
peptide sequence with various bulky groups resulted in
compounds displaying B2 receptor antagonistic activity, in
some cases (analogue I and V) comparable to that of the
Stewart’s peptide. Furthermore compound V, containing in
its N-terminal part positively charged residue (Adc), is
another example of the analogue not supporting our pre-
vious ﬁndings suggesting that basic or acidic residues have
an unfavourable inﬂuence on B2 antagonism.
Interestingly enough, all the new compounds inhibited the
vasodepressor response in the rat blood pressure test
(antagonistic activity) and at the same time they caused
contraction of the uterine tissue in the in vitro rat uterus test
(agonistic activity). This is believed to support the idea of the
presence of different types of BK receptor in the rat uterus
and blood vessels. Although there has been no evidence for
more than one gene for B2 receptor within a single species
and B2 receptor gene knockout mouse has entirely lost
responsiveness to exogenous BK (Borkowski et al. 1995),
alternative splicingofa singlegenetranscriptcannotberuled
out. Pharmacological discrepancies noticed with BK and its
antagonistscanbeexplainedinterms oftheirinteractionwith
orphanG-protein-coupledreceptors for whichligands are not
known(forexampleGPCR100(BoelsandSchaller2003))or
with B2 receptor existing in one of the few possible confor-
mations that results in stimulating the speciﬁc intracellular
effector (Kenakin 2001). Undoubtedly, further studies are
needed to conﬁrm these hypotheses.
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